VENTOLIN Drug Patent Profile
✉ Email this page to a colleague
When do Ventolin patents expire, and what generic alternatives are available?
Ventolin is a drug marketed by Glaxosmithkline and is included in seven NDAs.
The generic ingredient in VENTOLIN is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ventolin
A generic version of VENTOLIN was approved as albuterol sulfate by SUN PHARM INDUSTRIES on December 5th, 1989.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VENTOLIN?
- What are the global sales for VENTOLIN?
- What is Average Wholesale Price for VENTOLIN?
Summary for VENTOLIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| Clinical Trials: | 51 |
| Patent Applications: | 4,178 |
| Drug Prices: | Drug price information for VENTOLIN |
| Drug Sales Revenues: | Drug sales revenues for VENTOLIN |
| What excipients (inactive ingredients) are in VENTOLIN? | VENTOLIN excipients list |
| DailyMed Link: | VENTOLIN at DailyMed |
Recent Clinical Trials for VENTOLIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Alberta | Phase 1 |
| Canisius-Wilhelmina Hospital | Phase 3 |
| Hat Yai Medical Education Center | Phase 3 |
US Patents and Regulatory Information for VENTOLIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | VENTOLIN | albuterol | AEROSOL, METERED;INHALATION | 018473-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | VENTOLIN HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 020983-001 | Apr 19, 2001 | BX | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Glaxosmithkline | VENTOLIN | albuterol sulfate | SYRUP;ORAL | 019621-001 | Jun 10, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | VENTOLIN ROTACAPS | albuterol sulfate | CAPSULE;INHALATION | 019489-001 | May 4, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | VENTOLIN | albuterol sulfate | SOLUTION;INHALATION | 019773-001 | Apr 23, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VENTOLIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | VENTOLIN | albuterol | AEROSOL, METERED;INHALATION | 018473-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | VENTOLIN | albuterol sulfate | SYRUP;ORAL | 019621-001 | Jun 10, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | VENTOLIN | albuterol sulfate | SYRUP;ORAL | 019621-001 | Jun 10, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | VENTOLIN | albuterol sulfate | TABLET;ORAL | 019112-002 | Jul 10, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | VENTOLIN | albuterol sulfate | TABLET;ORAL | 019112-001 | Jul 10, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VENTOLIN
See the table below for patents covering VENTOLIN around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
